• General Dermatology
  • Eczema
  • Alopecia
  • Aesthetics
  • Vitiligo
  • COVID-19
  • Actinic Keratosis
  • Precision Medicine and Biologics
  • Rare Disease
  • Wound Care
  • Rosacea
  • Psoriasis
  • Psoriatic Arthritis
  • Atopic Dermatitis
  • Melasma
  • NP and PA
  • Skin Cancer
  • Hidradenitis Suppurativa
  • Drug Watch
  • Pigmentary Disorders
  • Acne
  • Pediatric Dermatology
  • Practice Management

Overview of Efalizumab Placebo- controlled Phase III Trials

Article

Efalizumab is a humanized IgG monoclonal antibody directed against the alpha chain of LFA-1 (CD11a) expressed on the surface of T cells.11 Efalizumab blocks the interaction between LFA-1 and ICAM-1 on APCs, vascular endothelial cells, and cells in the dermis and epidermis.

Related Videos
© 2024 MJH Life Sciences

All rights reserved.